The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

  • S Horwitz
  • , O A O'Connor
  • , B Pro
  • , L Trümper
  • , S Iyer
  • , R Advani
  • , N L Bartlett
  • , J H Christensen
  • , F Morschhauser
  • , E Domingo-Domenech
  • , G Rossi
  • , W S Kim
  • , T Feldman
  • , T Menne
  • , D Belada
  • , Á Illés
  • , K Tobinai
  • , K Tsukasaki
  • , S-P Yeh
  • , A Shustov
    • A Hüttmann, K J Savage, S Yuen, P L Zinzani, H Miao, V Bunn, K Fenton, M Fanale, M Puhlmann, T Illidge

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Immunology and Microbiology

Agricultural and Biological Sciences